Roche in Russia Roche.com Contacts Site Map Font size home About Roche Products Research Diseases Press center RIME (For Professionals) The drug Hemlibra, the world's first drug for the treatment of hemophilia A with subcutaneous administration, is registered in Russia Why doesn't our immune system see cancer? What is idiopathic pulmonary fibrosis? Research recruitment New therapy for multiple sclerosis Cancer immunotherapy Rosh-TV Live Medical Information Service Medicines and quality Hotline for counterfeits A new indication for the treatment of breast cancer news Moscow, November 16, 2018 Published instructions for the drug Valcyte / film-coated tablets, 450 mg / Moscow, 06 November 2018 Published instructions for the drug Pegasys / solution for subcutaneous administration 135 mcg / 0.5 ml and 180 mcg / 0.5 ml / Moscow, 06 November 2018 Published instructions for the drug Kadsila / lyophilisate for the preparation of a concentrate for the preparation of a solution for infusion 100 mg, 160 mg / Moscow, 06 November 2018 Instructions for MabThera have been published / solution for subcutaneous administration 1400 mg / 11.7 ml / Moscow, 02 November 2018 Published instructions for the drug Hemlibra / solution for subcutaneous administration of 30 mg / ml and 150 mg / ml / All news Legal agreement Confidentiality © 2018 JSC "Rosh-Moscow" 31.10.2018 This website contains information for patients and specialists in the field of medicine and pharmaceuticals in Russia, and may contain information on Roche products that, for one reason or another, is not available or is not officially approved in your country. The information on this site should not be used for self-diagnosis and treatment and cannot be a substitute for an in-person consultation with a doctor.